This 100% online Postgraduate diploma will provide you with the skills and knowledge necessary to face the challenges in the Clinical and Molecular Management of Infections Caused by Multidrug-Resistant Bacteria"

Due to the rise of antimicrobial resistance, it is essential to adopt integrated approaches, combining advanced molecular diagnostic techniques with antimicrobial stewardship strategies. These measures not only optimize individualized treatment, minimizing the inappropriate use of antibiotics, but also play a crucial role in containing the spread of resistance in clinical and community settings. 

This is how this Postgraduate diploma is born, which will delve into the multifaceted causes of bacterial resistance to antibiotics, from the shortage of new antimicrobial agents, to socioeconomic influences and health policies. In doing so, practitioners will examine the global situation of antimicrobial resistance, with up-to-date statistics and regional trend analysis, equipping them with an informed and critical perspective to address this evolving phenomenon. 

In addition, the study plan will focus on the management of patients in Intensive Care Units (ICU), emphasizing the accurate diagnosis and effective treatment of common infections caused by multidrug-resistant bacteria. Pharmacists will also acquire specialized skills to implement prevention strategies to reduce the incidence and spread of these critical infections in highly complex hospital environments, contributing to the comprehensive management of antimicrobial resistance in the clinical setting. 

Finally, the syllabus will focus on proteomics in Clinical Microbiology, providing advanced knowledge on protein separation and identification techniques, both qualitative and quantitative. In addition, bioinformatics tools for proteomic and genomic analysis will be applied, therefore strengthening the investigation of resistance mechanisms and the development of personalized therapeutic strategies. 

The detailed resources will offer graduates an online methodology, allowing them to organize their study schedule according to their personal and professional commitments. In addition, the advanced Relearning system will be incorporated, which facilitates deep understanding of key concepts through strategic repetition. Therefore, they will be able to learn at their own pace and fully master the latest scientific evidence available. 

You will be prepared to lead scientific and clinical initiatives that promote progress in the management of infections caused by Multidrug-Resistant Bacteria, through the extensive library of multimedia resources offered by TECH"

This Postgraduate diploma in Clinical and Molecular Management of Infections Caused by Multidrug-Resistant Bacteria contains the most complete and up-to-date scientific program on the market. The most important features include:

• The development of practical cases presented by experts in Microbiology, Medicine and Parasitology
• The graphic, schematic and eminently practical contents with which it is conceived gather scientific and practical information on those disciplines that are indispensable for professional practice 
• Practical exercises where the self-assessment process can be carried out to improve learning
• Its special emphasis on innovative methodologies 
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments 
• Content that is accessible from any fixed or portable device with an Internet connection

You will delve into advanced protein separation and identification techniques, both qualitative and quantitative, essential for understanding bacterial resistance at the molecular level. What are you waiting for to enroll?" 

The program’s teaching staff includes professionals from the field who contribute their work experience to this educational program, as well as renowned specialists from leading societies and prestigious universities. 

The multimedia content, developed with the latest educational technology, will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide immersive education programmed to learn in real situations. 

This program is designed around Problem-Based Learning, whereby the professional must try to solve the different professional practice situations that arise during the course. For this purpose, students will be assisted by an innovative interactive video system created by renowned and experienced experts. 

You will examine the various causes of antimicrobial resistance, ranging from shortages of new antibiotics to socioeconomic factors and public health policies. With all TECH's quality guarantees!"

You will acquire specialized knowledge on the diagnosis and treatment of the most frequent infections in critical environments, such as the ICU, thanks to the best teaching materials, at the technological and educational forefront"

This academic program will offer specialized qualification, addressing the crucial aspects of antimicrobial resistance and its clinical management. Therefore, the contents of the program will include a comprehensive analysis of the causes and mechanisms of bacterial resistance, from the lack of new antibiotics to socioeconomic factors and public health policies. The diagnosis and treatment of infections in critical environments such as intensive care units will also be discussed, with emphasis on strategies for the prevention and control of multidrug-resistant infections. In addition, advanced Proteomics and Genomics techniques applied to clinical microbiology will be examined. 

The program has been specifically designed to prepare pharmacists in the complexities of antimicrobial resistance, from the world's best digital university, according to Forbes"

Module 1. Multidrug-Resistant Bacteria in Human Pathology

1.1. Mechanisms of Acquired Resistance to Antibiotics

1.1.1. Acquisition of Resistance Genes
1.1.2. Mutations
1.1.3. Acquisition of Plasmids

1.2. Mechanisms of Intrinsic Resistance to Antibiotics

1.2.1. Blockage of Antibiotic Entry
1.2.2. Modification of the Antibiotic Target
1.2.3. Inactivation of the Antibiotic
1.2.4. Antibiotic Expulsion

1.3. Chronology and Evolution of Antibiotic Resistance

1.3.1. Discovery of Antibiotic Resistance
1.3.2. Plasmids
1.3.3. Evolution of Resistance
1.3.4. Current Trends in the Evolution of Antibiotic Resistance

1.4. Antibiotic Resistance in Human Pathology

1.4.1. Increased Mortality and Morbidity
1.4.2. Impact of Resistance on Public Health
1.4.3. Economic Cost Associated with Antibiotic Resistance

1.5. Multidrug-Resistant Human Pathogens

1.5.1. Acinetobacter Baumannii
1.5.2. Pseudomonas Aeruginosa
1.5.3. Enterobacteriaceae
1.5.4. Enterococcus Faecium
1.5.5. Staphylococcus Aureus
1.5.6. Helicobacter Pylori
1.5.7. Campylobacter Spp
1.5.8. Salmonellae
1.5.9. Neisseria Gonorrhoeae
1.5.10 Streptococcus Pneumoniae
1.5.11 Hemophilus Influenzae
1.5.12 Shigella Spp

1.6. Bacteria Highly Dangerous to Human Health: Update of the WHO List

1.6.1. Critical Priority Pathogens
1.6.2. High Priority Pathogens
1.6.3. Pathogens with Medium Priority

1.7. Analysis of the Causes of Antibiotic Resistance

1.7.1. Lack of New Antibiotics
1.7.2. Socioeconomic Factors and Health Policies
1.7.3. Poor Hygiene and Sanitation
1.7.4. Health Policies and Antibiotic Resistance
1.7.5. International Travel and Global Trade
1.7.6. Dispersal of High-Risk Clones
1.7.7. Emerging Pathogens with Resistance to Multiple Antibiotics

1.8. Antibiotic Use and Abuse in the Community

1.8.1. Prescription
1.8.2. Acquisition
1.8.3. Misuse of Antibiotics

1.9. Current Status of Antibiotic Resistance in the World

1.9.1. Global Statistics
1.9.2. Central and South America
1.9.3. Africa
1.9.4. Europe
1.9.5. North America
1.9.6. Asia and Oceania

1.10. Perspectives on Antibiotic Resistance

1.10.1. Strategies to Mitigate the Problem of Multidrug-Resistance
1.10.2. International Actions
1.10.3. Actions at the Global Level

Module 2. Management of Patients with Multidrug-Resistant Bacterial Infections in Intensive Care Units (ICU)

2.1. Colonization and Infection of Patients in ICUs

2.1.1. Types of ICUs
2.1.2. Epidemiology
2.1.3. Risk Factors Associated with Infection in ICUs

2.2. Impact of Nosocomial Infections in the Critically Ill Patient

2.2.1. Importance of Nosocomial Infections in ICUs
2.2.2. Risk Factors for Nosocomial Infections

2.2.2.1. Patient Factors
2.2.2.2. Factors of the ICU Environment
2.2.2.3. Factors Related to the Healthcare Personnel

2.2.3. Impact of Nosocomial Infections in Immunocompromised Patients
2.2.4. Impact on Length of Stay in the ICU

2.3. Pneumonia Associated with Mechanical Ventilation

2.3.1. Etiology
2.3.2. Diagnosis
2.3.3. Treatment

2.4. Urinary Tract Infections Associated with Catheters

2.4.1. Etiology
2.4.2. Diagnosis
2.4.3. Treatment

2.5. Primary Bacteremias and Catheter-Related Bacteremias

2.5.1. Etiology
2.5.2. Diagnosis
2.5.3. Treatment

2.6. Pseudomembranous Colitis

2.6.1. Etiology
2.6.2. Diagnosis
2.6.3. Treatment

2.7. Infections by Opportunistic Pathogens

2.7.1. Etiology
2.7.2. Diagnosis
2.7.3. Treatment

2.8. Appropriate Use of Antibiotics

2.8.1. Programs for the Optimization of Antibiotic use (PROA) in the ICU
2.8.2. Antibiotic Therapy Strategies for the Treatment of Gram-Negative Patients
2.8.3. Antibiotic Therapy Strategies for the Treatment of Gram-Positive Patients
2.8.4. Antibiotic Therapy Strategies for the Treatment of Co-Infections

2.9. Strategies for the Prevention of BMR Infections in the ICU

2.9.1. Hygiene Measures
2.9.2. Infection Control Measures
2.9.3. Protocols and Clinical Practice Guidelines
2.9.4. Education and Training of ICU Personnel
2.9.5. Participation of Patients and their Families

2.10. Infection Prevention Strategies in the ICU

2.10.1. Infection Prevention Strategies in the ICU According to the Focus

2.10.1.1. Pneumonia
2.10.1.2. Bacteremia
2.10.1.3. Urinary Infection

2.10.2. Evaluation and Quality Indicators in the Prevention of Infections
2.10.3. Evaluation and Continuous Improvement Tools
2.10.4. Successful Examples of Infection Prevention in ICUs

Module 3. Proteomics in Clinical Microbiology

3.1. Proteomics in the Microbiology Laboratory

3.1.1. Evolution and Development of Proteomics
3.1.2. Importance in Microbiological Diagnosis
3.1.3. Proteomics of Multi-Resistant Bacteria

3.2. Qualitative Protein Separation Techniques

3.2.1. Two-Dimensional Electrophoresis (2DE)
3.2.2. DIGE Technology
3.2.3. Applications in Microbiology

3.3. Quantitative Protein Separation Techniques

3.3.1. Isotopic Labelling
3.3.2. High Performance Liquid Chromatography (HPLC)
3.3.3. Mass Spectrometry (MS)

3.3.3.1. MALDI-TOF Technologies in the Clinical Microbiology Laboratory

3.3.3.1.1. VITEK®MS System
3.3.3.1.2. MALDI Biotyper® System

3.4. MALDI-TOF Applications in Clinical Microbiology

3.4.1. Identification of Microorganisms
3.4.2. Characterization of Antibiotic Resistance
3.4.3. Bacterial Typing

3.5. Bioinformatics Tools for Proteomics

3.5.1. Proteomic Databases
3.5.2. Protein Sequence Analysis Tools
3.5.3. Visualization of Proteomic Data

3.6. Genomics in the Microbiology Laboratory

3.6.1. Evolution and Development of Genomics
3.6.2. Importance in Microbiological Diagnosis
3.6.3. Genomics of Multi-Resistant Bacteria

3.7. Types of Sequencing

3.7.1. Sequencing of Genes with Taxonomic Value
3.7.2. Sequencing of Genes of Taxonomic Value
3.7.3. Bulk Sequencing

3.8. Applications of Massive Sequencing in Clinical Microbiology

3.8.1. Whole Bacterial Genome Sequencing
3.8.2. Comparative Genomics
3.8.3. Epidemiological Surveillance
3.8.4. Microbial Diversity and Evolution Studies

3.9. Bioinformatics Tools for Genomics

3.9.1. Genomic Databases
3.9.2. Sequence Analysis Tools
3.9.3. Visualization of Genomic Data

3.10. Future of Genomics and Proteomics in the Clinical Laboratory

3.10.1. Recent and Future Developments in Genomics and Proteomics
3.10.2. Development of New Therapeutic Strategies
3.10.3. Technical and Bioinformatics Challenges
3.10.4. Ethical and Regulatory Implications

You will acquire the necessary tools for accurate identification of microorganisms and personalization of treatment, therefore contributing to better management of these complex infections in your daily practice"